Scilex Holding Company announced that it has filed a New Drug Submission (NDS) to Health Canada?s Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for the approval of ELYXYB® for acute treatment of migraine with or without aura in Canada.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.83 USD | -14.88% |
|
+27.08% | -10.29% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-10.29% | 222M | |
+13.67% | 78.98B | |
+13.04% | 8.89B | |
-22.91% | 4.36B | |
+33.84% | 4.29B | |
+10.76% | 4.1B | |
+6.75% | 2.16B | |
-30.28% | 2.13B | |
+8.58% | 2.01B | |
-44.99% | 1.75B |
- Stock Market
- Equities
- SCLX Stock
- News Scilex Holding Company
- Scilex Holding Company Announces Filing of New Drug Submission to Health Canada's Pharmaceutical Drugs Director, Bureau of Cardiology, Allergy and Neurological Sciences for the Approval of ELYXYB® for Acute Treatment of Migraine With or Without Aura in Canada